Drug intelligence / Profile preview

Ankaferd Hemostat

Development stage
Unknown
Lead developer
AND İlaç
Administration
Topical, Oral
01

Overview

Ankaferd Hemostat (also known as Ankaferd Blood Stopper or ABS) is a unique, standardized herbal extract used primarily as a topical hemostatic agent. Developed in Turkey, it is composed of a specific mixture of five medicinal plants: *Thymus vulgaris* (thyme), *Glycyrrhiza glabra* (licorice), *Vitis vinifera* (grape), *Alpinia officinarum* (lesser galangal), and *Urtica dioica* (stinging nettle). Unlike traditional hemostats that act on the classical coagulation cascade, Ankaferd Hemostat induces the rapid formation of a protein network in the blood that serves as a focal point for erythrocyte aggregation. This mechanism is independent of coagulation factors II, VII, IX, and X, making it effective even in patients with primary or secondary hemostasis disorders. Beyond its hemostatic properties, the product has demonstrated anti-infective, anti-neoplastic, and wound-healing activities in various clinical and preclinical settings, including the management of gastrointestinal bleeding, surgical hemorrhages, and oral mucositis.

Brand names
Ankaferd Blood StopperAnkaferd Hemostat
Other names
Ankaferd
02

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on Ankaferd Hemostat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ankaferd Hemostat.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call